Organization
Capital Medical University
26 clinical trials
13 abstracts
Abstract
Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial.Org: Beijing Neurosurgical Institute, Capital Medical University, Department of Neurosurgery, Prince of Wales Hospital, Beijing Tiantan Hospital, The First Affiliated Hospital of Zhengzhou University,
Abstract
Initial results from phase I trial of a novel oncolytic adenovirus Ad-TD-nsIL12 in recurrent glioblastoma connecting to ventricular system.Org: Sanbo Brain Hospital, Capital Medical University, Beijing, China, Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute,
Clinical trial
A Multi-center, Random, Double Blind and Placebo Control Phase III Clinical Study on the Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular DementiaStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
The Effect of Ciprofol on Breathing Patterns, Respiratory Drive, and Inspiratory Effort in Mechanically Ventilated PatientsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Controlled Trial of the Efficacy of Combining Traditional Tibetan and Remote Ischemic Conditioning on High Altitude PolycythemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Abstract
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Second Department of Thoracic Tumors, Peking University Cancer Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology,
Clinical trial
The Impact of Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke Patients: A Prospective, Multicenter, Open-label, Randomized Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Abstract
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Science and Peking Union Medical College,
Abstract
Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Chaoyang Hospital, Capital Medical University,
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center II Clinical Trial to Evaluate the Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Mild to Moderate Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
The Efficacy and Safety of Esketamine for Rapid Treatment of Depressive Episodes With Suicidal Ideation in Mood Disorders: A Multicenter, Randomized Controlled StudyStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot StudyStatus: Completed, Estimated PCD: 2023-05-01
Clinical trial
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine GliomaStatus: Recruiting, Estimated PCD: 2025-01-04
Clinical trial
Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive ImpairmentStatus: Recruiting, Estimated PCD: 2024-01-04
Clinical trial
A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza AStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Exploratory Study Assessing the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension TreatmentStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK ImmunotherapyStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Mild and Moderate Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine GliomaStatus: Recruiting, Estimated PCD: 2025-01-04
Clinical trial
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation BurdenStatus: Withdrawn, Estimated PCD: 2021-12-30
Clinical trial
Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined Anti-PD1 in Advanced NSCLC: A Randomized Controlled TrialStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Statin for Neuroprotection in Spontaneous Intracerebral HemorrhageStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant MesotheliomaStatus: Terminated, Estimated PCD: 2021-12-31
Clinical trial
A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or MetastasesStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Multicenter Double-blind Randomized Controlled Trial of Systemic Corticosteroid Therapy in AECOPD Patients Admitted to Hospital With Higher Blood Eosinophil LevelsStatus: Not yet recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.Status: Active (not recruiting), Estimated PCD: 2023-03-02
Clinical trial
A Prospective Study of Anti-PD-1 Alone or Combined Wih Autologous DC-CIK Cell Therapy in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Randomized Controlled Trial Assessing the Efficacy and Safety of Normobaric Hyperoxia for Acute Ischemic Stroke Patients Undergoing Endovascular TreatmentStatus: Completed, Estimated PCD: 2023-05-05
Clinical trial
The Safety and Efficacy of Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke：A Randomized, Controlled Pilot StudyStatus: Completed, Estimated PCD: 2019-07-21
Abstract
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.Org: Lung Cancer Center, Shanghai Chest Hospital, Jiaotong University, Zhujiang Hospital of Southern Medical University, Guangzhou, China, Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,
Abstract
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.Org: Beijing Tiantan Hospital, Capital Medical University, Biomedical Analysis Center, Guangdong TCRCure Biopharma Technology Co., Ltd, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China,
Abstract
Investigation of synthetic lethality gene pairs in the DNA damage response pathway in response to immunotherapy in pan-cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Shijitan Hospital, Capital Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 3D Medicine Inc.,
Abstract
Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma.Org: Capital Medical University, Department of Human Cell Biology and Genetics, Southern University of Science and Technology School of Medicine, Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital,
Abstract
Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study.Org: Beijing Tian Tan Hospital, Capital Medical University, Capital Medical University, Beijing InnoCare Pharma Tech,
Abstract
Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: A single-arm, phase II trial.Org: Peking University School and Hospital of Stomatology, Beijing, China, Fu Xing Hospital, Capital Medical University, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China,
Abstract
Sensitive detection of CSF-derived cell-free DNA at the CNV level by shallow whole-genome sequencing for diagnosis and characterization of CNS metastases.Org: Beijing Tian Tan Hospital, Capital Medical University, Capital Medical University, Genetron Health (Beijing) Co. Ltd.,
Abstract
Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutated NSCLC with brain metastasis instructed by dynamic monitoring circulating tumor DNA of paired cerebrospinal fluid and plasma.Org: Beijing Tiantan Hospital, Beijing Tian Tan Hospital, Capital Medical University, Capital Medical University,
Clinical trial
Implementation Research on the Intervention Mode of " Comorbidity-Co-causes-Joint-prevention" Comprehensive Demonstration District of Depression and Obesity Among Children and Adolescents in BeijingStatus: Not yet recruiting, Estimated PCD: 2026-12-31